Molecular immune signatures of HIV-1 vaccines in human PBMCs

The global transcriptional profile of peripheral blood mononuclear cells (PBMCs) stimulated with HIV candidate vaccine (virus-like particles, VLPs) has been evaluated in HIV-infected patients with low/high viral load compared to healthy volunteers. Baseline activation of chemokine production was obs...

Full description

Saved in:
Bibliographic Details
Published in:FEBS letters 2009-09, Vol.583 (18), p.3004-3008
Main Authors: Monaco, Alessandro, Marincola, Francesco M., Sabatino, Marianna, Pos, Zoltan, Tornesello, Maria Lina, Stroncek, David F., Wang, Ena, Lewis, George K., Buonaguro, Franco M., Buonaguro, Luigi
Format: Article
Language:English
Subjects:
AIDS Vaccines - pharmacology
Case-Control Studies
Chemokines - biosynthesis
Gene Expression Profiling - methods
HIV Infections
HIV-1
Human immunodeficiency virus 1
Humans
Immunity, Innate - genetics
Immunogenomics
Leukocytes, Mononuclear - drug effects
Peripheral blood mononuclear cell
Vaccine
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The global transcriptional profile of peripheral blood mononuclear cells (PBMCs) stimulated with HIV candidate vaccine (virus-like particles, VLPs) has been evaluated in HIV-infected patients with low/high viral load compared to healthy volunteers. Baseline activation of chemokine production was observed in PBMC from HIV-infected patients and innate immune stimulation with HIV-VLPs was not blunted. The immune profile among HIV-infected patients was found to be qualitatively similar but quantitatively extremely variable. This diversity was independent of viral load and it might be dependent on individual immunogenetic traits or concurrent immunological status. This ex vivo screening strategy represents an efficient tool for guiding modifications/optimizations of vaccination strategies and understanding failures in individuals enrolled in clinical trials.
ISSN:0014-5793
1873-3468
DOI:10.1016/j.febslet.2009.07.060